MedTrace Logo

A Study to Evaluate the Human Tolerance and Pharmacokinetics of LY03003

NCT04627155 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2020-11-13

No results posted yet for this study

Summary

This study is to evaluate the human tolerance and pharmacokinetics of LY03003.

Conditions

  • Parkinson Disease

Interventions

DRUG

LY03003

Rotigotine,extended-release microspheres

Sponsors & Collaborators

  • Luye Pharma Group Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-03-15
Primary Completion
2013-05-20
Completion
2013-05-20

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04627155 on ClinicalTrials.gov